---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-011110"
form_type: "8-K"
ticker: "IBAC"
cik: "0001998781"
company_name: "IB Acquisition Corp."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:58:24.722416+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GNQ Insilico enters collaboration with Fortune 100 tech firm for AI-driven drug discovery

## Summary
- GNQ Insilico signed a Joint Initiative Agreement with a Fortune 100 global technology company.
- Collaboration combines GNQ's AI platforms with partner's consulting, cloud, and quantum computing.
- Initial term of two years, global territory, non-exclusive, with option to extend.
- Partnership aims to advance AI-driven drug discovery and precision medicine solutions.
- Relates to proposed business combination between IB Acquisition Corp. (IBAC) and GNQ.

## SEC filing metadata
- accession: 0001493152-26-011110
- form_type: 8-K
- ticker: IBAC
- cik: 0001998781
- company_name: IB Acquisition Corp.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1998781/000149315226011110/0001493152-26-011110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1998781/000149315226011110/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-011110
- JSON: https://secwatch.observer/filing/0001493152-26-011110.json
- Plain text: https://secwatch.observer/filing/0001493152-26-011110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.